Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 3, 2003, Pages 331-338

  Haddad, Robert I ^a   Wirth, Lori ^a   Posner, Marshall R ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Concomitant chemoradiation; Head and neck cancer; Induction chemotherapy; Sequential chemoradiation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; PACLITAXEL;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; NEUROPATHY; NEUTROPENIA; ORGAN PRESERVATION; POPULATION RESEARCH; REVIEW;

EID: 0037531704     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.3.331     Document Type: Review

References (32)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Medical progress: head and neck cancer. N. Engl. J. Med. 345 (26), 1890-1900 (2001).
2. Vokes E, Kies M, Haraf D et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J. Clin. Oncol. 18, 1652-1661 (2000).
3. Robbins KT, Kumar P, Regine WF et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int. J. Radiat, Oncol Biol. Phys. 38(2), 263-271 (1997).
4. Adelstein DJ. Induction chemotherapy in head and neck cancer Hematol. Oncol. Clin. North Am. 13(4), 689-698 (1999).
5. Harari P. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J. Clin. Oncol. 15, 2050-2055 (1997).
6. Rooney M, Kish J, Jacobs J et al. Improved complete response rate and survival in advanced head and neck cancer. Cancer 55, 1123-1128 (1985).
7. Pignon J, Bourhis J, Domenge C, Designe L, Group M-NC. Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: three meta-analyses of updated individual data. Lancet 355, 949-955(2000).
8. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann. Oncol 13, 995-1006 (2002).
9. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med. 324, 1685-1689 (1991).
10. Lefebvre J, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. J. Natl. Cancer Inst. 88(13), 890-498 (1996).
11. Domenge C, Hill C, Lefebvre J et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br. J. Cancer 83(12), 1594-1598 (2000).
12. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in Stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del collo J. Natl Cancer Inst. 86, 265-272 (1994).
13. Colevas A. Docetaxel in squamous cell carcinoma of the head and neck. Cancer Invest. 17, 62-63 (1998).
14. Catimel G, Verwij J, Hanauske A. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 5, 553-537 (1994).
15. Colevas A, Busse P, Norris C et al. Induction chemotherapy with docetaxel; cisplatin, 5-fluorouracil and leucovorin (TPFL5) for squamous cell carcinoma of the head and neck: a Phase I/II trial. J. Clin. Oncol. 16,1331-1339 (1998).
16. Colevas A, Norris C, Tishler R et al. A Phase II trial of TPFL (docetaxel, cisplatin, 5-fluorouracil, leucovorin) as induction for squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol 17(11), 3503-3511 (1999).
17. Colevas AD, Norris CM, Tishler RB et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am. J. Clin. Oncol. 25(2), 153-159 (2002).
18. Posner M, Glisson B, Frenette G et al. A multi-center Phase I-II trial of docetaxel, cisplatinum and 5-fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol. 19, 1096-1104 (2001).
19. Haddad R, Norris C, Sulivan C et al. Docetaxel, cisplatin and 5-fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana-Farber Cancer Institute experience. Cancer 97(2), 412-418 (2003).
20. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J. Natl. Cancer Inst. 91, 2081-2086 (1999).
21. Sutharalingum M, Haas M, Conley B et al. The use of carboplatinum and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int. J. Rad. Biol. Oncol. Phys. 47, 49-56 (2000).
22. Brizel D, Albers M, Fisher S et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338, 1798-1804 (1998).
23. Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head and neck cancer. Int. J. Rad. Biol. Oncol. Phys. 50(5), 1161-1171 (2001).
24. Fu K, Pajak T, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J. Rad. Biol. Oncol. Phys. 48, 7-16 (2000).
25. Adelstein D, Li Y, Adams G et al. An Intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21, 92-98 (2003).
26. Forastiere AA, Berkey B, Maor M et al. Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11. Proc. Am. Soc. Clin. Oncol. 20(1) (200 1) (Abstract 4).
27. Machtay M, Rosenthal DI, Hershock D et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal. carcinoma: a University of Pennsylvania Phase II trial. J. Clin. Oncol. 20(19), 3964-3971(2002).
28. Vokes EE, Stenson K Rosen FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J. Clin. Oncol. 21(2), 320-326(2003).
29. Gray J, Meluch A, Greco F et al. Induction paclitaxel/carboplatin/5-FU followed by concurrent radiotherapy and weekly paclitaxel/carboplatin for patients with locally advanced head and neck cancer (HNC): a Minnie Pearl Cancer Research Network Trial. Proc. Am. Soc. Clin. Oncol. 20(1), (2001) (Abstract 226).
30. Urba S, Moon J, LeBlanc M et al. Induction chemotherapy followed by chemoradiation for organ preservation in patients (pts) with advanced resectable cancer of the base of tongue (BOT) and hypopharynx (HP): a Southwest Oncology Group trial. Proc. Am. Soc. Clin. Oncol. 21(1), (2002) (Abtract 230).
31. Posner M, Colevas A, Tishler R. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin. Oncol. 27(Suppl. G), 13-24 (2000).
32. Cognetti F, Pinnaro P, Ruggeri EM et al. Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin. Oncol. 7(7), 829-837 (1989).